The International Society of Microbiota was founded by Marvin Edeas. The idea of ISM was born after the transformation of the Task Force Mitochondria-Microbiota to larger group gathering all actors and experts working in the field of microbiota. The idea is to bring a new level of thinking and understanding of microbiota science out of the classical existing point of view.

ISM is a non-profit-making international organization. In no case, part of its assets or incomes shall benefit to any private or individual partnership or corporation.

Founder and Executive Chairman:
Prof. Marvin Edeas, Institut Cochin, INSERM U1016, University Paris Descartes, France

Current President of ISM:
Prof. Peter C. Konturek, Thuringia-Clinic Saalfeld, Germany

The aims of ISM are to:
1. ISM offer a new perspective and solutions for microbiota and health: the dynamic microbiota research,
2. Advance the practical applications of microbiota and their metabolites in all related fields, with particular reference to health and nutrition,
3. Analyse and provide recommendations to ISM’s members, health decision makers and institutions about the last microbiota researches, uses and problems. This analysis will be done by international qualified team members of ISM,
4. Transfer the basic researches and data into a real clinical, pharmaceutical and cosmetics applications,
5. Transfer the basic researches and data into a real nutritional and nutraceutical applications in food technology,
6. Encourage communication and interaction among researchers, physicians, nutritionists, industrials, food technology and strategic marketing managers through a global microbiota network,
7. Increase integration and interaction of the various disciplines involved in microbiota fields.

Why an International Society dedicated to Microbiota?
We can divide our task force in four targets:

1. Targeting the Science
More scientific research needed to profile and analyze the diversity of microbiota of each person.
The sequencing of human microbiota progress and many innovations will be presented during Institut Pasteur Meeting.
We look to set up a kind of individual profile to be used as a biomarker of many chronic diseases.

2. Targeting the Diversity of Population
ISM will take on consideration the variability, the heterogeneity of populations and their diets.
3. Targeting the Industrial Translation

The industrial vision of microbiota must be **re-designed** and re-think.

“...we cannot consider one microbiota strain can treat one precise pathology and fit with all population coming from different cultures…”

The ISM needs to reposition the strategy: the ISM task force proposes to analyze the metabolites first, reformulate later and provide it to people **rather than** providing the microbiota strain.

The scientific committee of ISM will double efforts to better understand the quality of metabolite and undertake clinical studies with this metabolite rather the strain.

4. Targeting EFSA regulatory

How to explain the rejection of all claims provided by industries?

The industries and EFSA experts considered the gut microbiota with pharmaceutical frame and strict standard.

While the science of gut and microbiota is a dynamic field, with a huge evolution and affected by multifactor to modulate its functioning.

ISM will bring this new dynamic point of view to accelerate the credible translation of this science into real benefit for the consumer.

A specific meeting with EFSA experts will be scheduled to share our point of view.

ISM offers a new platform connecting industries, scientists and regulatory bodies.

This platform is located in Tokyo - Japan.

---

**International Society of Microbiota**

Email: microbiota@microbiota-site.com

To access to all advantages of ISM Membership, register on:

[www.microbiota-site.com](http://www.microbiota-site.com)